IQVIA Holdings Inc., a global leader in clinical research services and healthcare analytics, has released its financial results for the first quarter of 2026, revealing robust growth and ongoing strategic initiatives. With a workforce of approximately 93,000 employees spanning over 100 countries, IQVIA remains committed to enhancing patient outcomes and supporting the life sciences sector through innovative solutions powered by its proprietary IQVIA Connected Intelligence™ platform.

2. Segment Reporting Restructuring

A significant change in IQVIA's operational structure took effect on January 1, 2026. The company consolidated its three previous reporting segments—Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions—into two streamlined segments: Commercial Solutions and Research & Development Solutions. This restructuring aims to align more closely with evolving industry standards and enhance operational efficiency.

Commercial Solutions and Research & Development Solutions

Commercial Solutions merges critical patient engagement services, analytics, and technology solutions, while Research & Development Solutions focuses on outsourced clinical research and real-world offerings.

3. Revenue Performance

In Q1 2026, IQVIA reported total revenues of $4.15 billion, marking an 8.4% increase or $322 million compared to the same quarter in 2025. This growth was driven by a constant currency revenue increase of approximately $228 million, with notable contributions from both segments:

Commercial Solutions generated revenues of $1,754 million, reflecting an 11.6% increase year-over-year, primarily due to a rise in patient solutions and commercial engagement services.

Research & Development Solutions reported revenues of $2,397 million, up 6.2% from the previous year, attributed to increased clinical services and lab testing demand.

Income Statement of Iqvia Holdings Inc

	May 2025	May 2026
Net Income	1.33B	1.38B
Net Income to Non-controlling Interest	0	2M
Profit	1.33B	1.38B
Net Income Continuing	1.33B	1.34B
Income Tax Expense	313M	250M
Pretax Income	1.65B	1.59B
Non-operating Income	-540M	-604M
Operating Income	2.19B	2.2B
Revenue	15.49B	16.63B
Costs and Expenses	13.30B	14.43B
Cost of Revenue	10.11B	11.14B
Operating Expenses	3.18B	3.28B
Depreciation, Depletion & Amortization	1.11B	1.16B
Restructuring Charge	81M	127M
Selling, General & Administrative	1.99B	1.99B

4. Operating Costs and Expenses

The rise in revenues was accompanied by increased operational costs. In Q1 2026, the total cost of revenues (excluding depreciation and amortization) rose by $265 million, driven by higher compensation and operational expenses. Selling, general, and administrative expenses saw a minor decline of $6 million, showcasing a nuanced balance between segment growth and corporate expense management.

Restructuring Costs

As part of ongoing efforts to optimize operations, IQVIA incurred restructuring costs totaling $51 million in Q1 2026. These initiatives are designed to streamline global operations and align resources more effectively with client needs, with a continued focus on reducing overcapacity.

5. Geographic Performance

Approximately 30% of IQVIA's revenues in the first quarter were derived from non-U.S. dollar currencies, highlighting the company's significant international footprint. Management noted that fluctuations in foreign currency exchange rates could materially impact financial results going forward.

6. Key Financial Metrics

As of March 31, 2026, IQVIA's cash balance stood at $1,947 million, slightly lower than the $1,980 million reported at the end of 2025. The company remains focused on maintaining liquidity through strong operating cash flows, while also exploring potential financing opportunities.

Equity Repurchase Program

IQVIA has an equity repurchase authorization of $13,725 million, of which $552 million was utilized to repurchase 3.2 million shares during Q1 2026. The company retains $1,217 million in remaining authorization, signaling confidence in its long-term value and commitment to shareholder returns.

7. Debt Management

IQVIA's total indebtedness as of March 31, 2026, was $15,908 million. The company entered into a 364-Day Term A Loan Agreement for $650 million in March, which was used to refinance existing senior notes. Management confirmed compliance with all debt covenants, indicating a stable financial outlook.

Balance Sheet of Iqvia Holdings Inc

	May 2025	May 2026
Total Assets	27.32B	29.67B
Total Current Assets	5.91B	6.22B
Cash and Equivalents	1.74B	1.94B
Short-term Investments	136M	156M
Non-trade Receivables	43M	29M
Prepaid Expenses	166M	167M
Other Current Assets	3.82B	3.92B
Total Non-current Assets	21.41B	23.45B
Intangible Assets	19.53B	21.34B
Long-term Investments	253M	357M
Non-current Deferred Tax Assets	245M	358M
Net PP&E	533M	516M
Lease Assets	235M	293M
Other Non-current Assets	615M	584M
Total Liabilities and Equity	27.32B	29.67B
Total Liabilities	21.33B	23.32B
Total Current Liabilities	7.17B	8.32B
Accounts Payable and Accrued Liabilities	3.69B	3.81B
Current Debt	1.22B	1.84B
Current Deferred Revenue	1.94B	2.26B
Other Current Liabilities	319M	413M
Total Non-current Liabilities	14.15B	14.99B
Long-term Debt	13.10B	13.98B
Non-current Deferred Tax Liabilities	197M	159M
Other Non-current Liabilities	853M	849M
Total Equity and Non-controlling Interests	5.98B	6.34B
Total Equity	5.97B	6.22B
Non-controlling Interests	8M	128M

8. Conclusion

IQVIA Holdings Inc. has demonstrated resilience and adaptability in a dynamic market. The company's strategic restructuring, alongside significant revenue growth and prudent cost management, positions it well for future success. As healthcare continues to evolve, IQVIA's commitment to leveraging advanced analytics and AI remains central to its mission of driving innovation and improving patient outcomes in the life sciences industry.

With ongoing strategic collaborations and a focus on international growth, IQVIA is poised for further advancements in the coming quarters.

Original filing: sec.gov